Sangamo Therapeutics, Inc (SGMOQ) stock
SGMOQOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q1 năm tài chính 2026, quý kết thúc ngày Mar 31, 2026Last filing: 10-Q on May 14, 2026Score 4/30
$0.10−0.01 (-8.17%)
Close on Oct 19, 2026Market cap $39.43MP/E –Yield –
Sangamo Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Sangamo Therapeutics's total assets was $59.97M at Mar 31, 2026. For fiscal 2025 it was $59.75M, down 41.2% from the year before. Over ten years it grew -12.1% a year on average. The highest annual figure on record is $938.55M in fiscal 2020.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $59.75M | -41.2% |
| FY2024 | Dec 31, 2024 | $101.64M | -38.5% |
| FY2023 | Dec 31, 2023 | $165.32M | -70.6% |
| FY2022 | Dec 31, 2022 | $562.51M | -22.1% |
| FY2021 | Dec 31, 2021 | $721.92M | -23.1% |
| FY2020 | Dec 31, 2020 | $938.55M | +47.2% |
| FY2019 | Dec 31, 2019 | $637.52M | +8.0% |
| FY2018 | Dec 31, 2018 | $590.40M | +105.9% |
| FY2017 | Dec 31, 2017 | $286.74M | +81.6% |
| FY2016 | Dec 31, 2016 | $157.89M | -27.3% |
| FY2015 | Dec 31, 2015 | $217.24M | -10.7% |
| FY2014 | Dec 31, 2014 | $243.21M | +72.7% |
| FY2013 | Dec 31, 2013 | $140.84M | +70.6% |
| FY2012 | Dec 31, 2012 | $82.53M | -5.5% |
| FY2011 | Dec 31, 2011 | $87.34M | +38.6% |
| FY2010 | Dec 31, 2010 | $63.00M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | $59.97M | -30.4% |
| Q4 FY2025 | Dec 31, 2025 | $59.75M | -41.2% |
| Q3 FY2025 | Sep 30, 2025 | $88.64M | -20.3% |
| Q2 FY2025 | Jun 30, 2025 | $97.56M | +4.9% |
| Q1 FY2025 | Mar 31, 2025 | $86.17M | -33.2% |
| Q4 FY2024 | Dec 31, 2024 | $101.64M | -38.5% |
| Q3 FY2024 | Sep 30, 2024 | $111.26M | -49.4% |
| Q2 FY2024 | Jun 30, 2024 | $93.01M | -71.4% |
| Q1 FY2024 | Mar 31, 2024 | $128.96M | -70.7% |
| Q4 FY2023 | Dec 31, 2023 | $165.32M | -70.6% |
| Q3 FY2023 | Sep 30, 2023 | $219.70M | -63.0% |
| Q2 FY2023 | Jun 30, 2023 | $325.07M | -47.3% |
| Q1 FY2023 | Mar 31, 2023 | $440.57M | -32.7% |
| Q4 FY2022 | Dec 31, 2022 | $562.51M | -22.1% |
| Q3 FY2022 | Sep 30, 2022 | $593.91M | -23.1% |
| Q2 FY2022 | Jun 30, 2022 | $617.13M | -26.1% |
| Q1 FY2022 | Mar 31, 2022 | $654.31M | -25.4% |
| Q4 FY2021 | Dec 31, 2021 | $721.92M | -23.1% |
| Q3 FY2021 | Sep 30, 2021 | $772.40M | -19.9% |
| Q2 FY2021 | Jun 30, 2021 | $835.36M | -6.6% |
| Q1 FY2021 | Mar 31, 2021 | $877.10M | +50.1% |
| Q4 FY2020 | Dec 31, 2020 | $938.55M | +47.2% |
| Q3 FY2020 | Sep 30, 2020 | $963.71M | +50.5% |
| Q2 FY2020 | Jun 30, 2020 | $894.66M | +32.8% |
| Q1 FY2020 | Mar 31, 2020 | $584.28M | +7.7% |
| Q4 FY2019 | Dec 31, 2019 | $637.52M | +8.0% |
| Q3 FY2019 | Sep 30, 2019 | $640.22M | +5.5% |
| Q2 FY2019 | Jun 30, 2019 | $673.48M | +7.3% |
| Q1 FY2019 | Mar 31, 2019 | $542.73M | +93.0% |
| Q4 FY2018 | Dec 31, 2018 | $590.40M | +105.9% |
| Q3 FY2018 | Sep 30, 2018 | $606.60M | +124.8% |
| Q2 FY2018 | Jun 30, 2018 | $627.73M | +121.8% |
| Q1 FY2018 | Mar 31, 2018 | $281.17M | +91.5% |
| Q4 FY2017 | Dec 31, 2017 | $286.74M | +81.6% |
| Q3 FY2017 | Sep 30, 2017 | $269.79M | +63.5% |
| Q2 FY2017 | Jun 30, 2017 | $282.99M | +56.4% |
| Q1 FY2017 | Mar 31, 2017 | $146.81M | – |
| Q4 FY2016 | Dec 31, 2016 | $157.89M | – |
| Q3 FY2016 | Sep 30, 2016 | $164.98M | – |
| Q2 FY2016 | Jun 30, 2016 | $180.91M | – |
See a number that looks wrong?